Tips from Other Journals

Levomethadyl Acetate for Opioid-Dependent Patients



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1998 Mar 15;57(6):1412.

Levomethadyl acetate hydrochloride (also known as LAAM) was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence. Unlike methadone, which requires daily administration, LAAM is administered three times a week. Eissenberg and colleagues compared the clinical efficacy of different dosages of LAAM.

Patients in the randomized, controlled study were assigned to one of three treatment groups, with the drug given on Mondays, Wednesdays and Fridays: low-dose LAAM (25 mg, 25 mg and 35 mg), medium-dose LAAM (50 mg, 50 mg and 70 mg) and high-dose LAAM (100 mg, 100 mg and 140 mg). The Friday dosages were higher to compensate for the longer dosage interval between Friday and Monday. The low-, medium- and high-dose groups had 62, 59 and 59 patients, respectively. Treatment goals were established for each patient, and individual and group therapy was provided. Patients' self-reports of illicit drug use and observed urine specimens were also obtained on the dosing days. Of the 180 patients who entered the study, 108 (60 percent) completed the entire 17-week study. No significant differences in retention were noted among the three treatment groups.

The percentage of patients who remained abstinent from opioid use (as verified by urine samples) increased as the LAAM dosage increased, with 11 percent of the low-dose group and 14 percent of the medium-dose group remaining abstinent for four consecutive weeks, compared with 34 percent of the high-dose group. Self-reported heroin use decreased to a greater degree in the high-dose group. After 16 weeks of LAAM treatment, patients in the high-dose group reported that they used heroin on 2.5 days of the previous 30 days, compared with 4.1 days and 6.3 days of the previous 30 days in the medium- and low-dose groups, respectively. Adverse effects were not dosage-related, and the most common adverse effect was constipation.

The authors conclude that LAAM treatment of opioid dependence has several advantages over the more commonly used methadone treatment—administering doses three times a week is more convenient and decreases the need for patients to take their medication at home. High-dose LAAM appears to be more effective than lower doses in decreasing heroin use.

Eissenberg T, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. JAMA. 1997;277:1945–51.



Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article